NCT00624832 - A Study of Efficacy of New Doses of Xolair to Protect From Allergen Challenge in Groups of Asthma Patients Defined by IgE Levels | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions

Asthma

Interventions

DRUG

Xolair

Xolair (Omalizumab) dose: 2 x 450 mg, 2 x 525 mg or 2 x 600 mg; subcutaneous injection;

DRUG

Placebo

Matching placebo of Xolair (omalizumab), by subcutaneous injection of a solution with a concentration of 125 mg/mL in a supine position.

Trial Locations (6)

Novartis Investigator Site, Berlin

Novartis Investigator Site, Frankfurt

Novartis Investigator Site, Munich

Novartis Investigator Site, Groningen

Novartis Investigator Site, Bloemfontein

Novartis Investigator Site, Durban